Will you have Repetitive speech with Ampyra - from FDA reports


Repetitive speech is found among people who take Ampyra, especially for people who are female, 60+ old , have been taking the drug for 2 - 5 years, also take medication Tecfidera, and have Gait disturbance. This study is created by eHealthMe based on reports of 57,233 people who have side effects when taking Ampyra from FDA, and is updated regularly.

What's eHealthMe?

eHealthMe is a health data analysis company based in Mountain View, California. eHealthMe monitors and analyzes the outcomes of drugs and supplements that are currently on the market. The results are readily available to health care professionals and consumers.

eHealthMe has released original studies on market drugs and worked with leading universities and institutions such as IBM, London Health Science Centre, Mayo Clinic, Northwestern University and VA. eHealthMe studies have now been referenced in over 500 peer-reviewed medical publications.

How we gather our data?

Healthcare data is obtained from a number of sources including the Food and Drug Administration (FDA). This information is aggregated and used to produce personalized reports that patients can reference.

The information that eHealthMe collects includes:

  • Side effects (including severity and how people recover from them)
  • Associated conditions or symptoms
  • Drug effectiveness
  • Demographic data regarding drug use

How the study uses the data?

The study is based on dalfampridine (the active ingredients of Ampyra) and Ampyra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Synonyms of Repetitive speech are also considered in the study.

What is Ampyra?

Ampyra has active ingredients of dalfampridine. It is often used in multiple sclerosis. (latest outcomes from Ampyra 57,350 users)

What is Repetitive speech?

Repetitive speech has been reported by people with multiple sclerosis, schizophrenia, depression, attention deficit hyperactivity disorder, obsessive-compulsive disorder (latest reports from 530 Repetitive speech patients).

How to use the study?

Patients can bring a copy of the report to their healthcare provider to ensure that all drug risks and benefits are fully discussed and understood. It is recommended that patients use the information presented as a part of a broader decision-making process.

On Mar, 14, 2019

57,233 people reported to have side effects when taking Ampyra.
Among them, 6 people (0.01%) have Repetitive speech

Number of reports submitted per year:

Could Ampyra cause Repetitive speech?

Time on Ampyra when people have Repetitive speech *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 0.0 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 100 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Repetitive speech when taking Ampyra *:

  • female: 83.33 %
  • male: 16.67 %

Age of people who have Repetitive speech when taking Ampyra *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 40 %
  • 50-59: 0.0 %
  • 60+: 60 %

Top conditions involved for these people *:

  1. Gait Disturbance: 1 person, 16.67%

Top co-used drugs for these people *:

  1. Tysabri: 2 people, 33.33%
  2. Tecfidera: 2 people, 33.33%
  3. Proscar: 1 person, 16.67%
  4. Neurontin: 1 person, 16.67%
  5. Ditropan: 1 person, 16.67%
  6. Copaxone: 1 person, 16.67%
  7. Baclofen: 1 person, 16.67%
  8. Avonex: 1 person, 16.67%
  9. Aubagio: 1 person, 16.67%

Top other side effects for these people *:

  1. Multiple Sclerosis Relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 4 people, 66.67%
  2. Mobility Decreased (ability to move is reduced): 4 people, 66.67%
  3. Weakness: 2 people, 33.33%
  4. Pain In Extremity: 2 people, 33.33%
  5. Motor Dysfunction (dysfunction of a muscle, nerve, or centre that effects or produces motion): 2 people, 33.33%
  6. Irritability: 2 people, 33.33%
  7. Hypotonia (low muscle tone): 2 people, 33.33%
  8. Fall: 2 people, 33.33%
  9. Cognitive Disorder (mental health disorders affects learning, memory, perception, and problem solving): 2 people, 33.33%
  10. Balance Disorder: 2 people, 33.33%

* Approximation only. Some reports may have incomplete information.

Do you have Repetitive speech while taking Ampyra?

You are not alone:

Related studies

Drugs that are associated with Repetitive speech
Repetitive speech (322 drugs)
Could your condition cause Repetitive speech
Repetitive speech (194 conditions)
Ampyra side effects

Browse side effects by gender and age

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Ampyra
a b c d e f g h i j k l m n o p q r s t u v w x y z
Compare Ampyra with similar drugs

What would happen?

Predict new side effects and undetected conditions when you take Ampyra and have Repetitive speech

FDA reports used in this study

Recent updates

Recent general studies
Recent personal studies

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.